The Pharma Letter13h
Qfitlia scores a first with FDA approval
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for ...
The Pharma Letter8h
Lilly reports lasting drop in heart risk factor with new drug
US pharma major Eli Lilly (NYSE: LLY) has unveiled new Phase II data showing that its RNA-based therapy lepodisiran produced ...